Market Overview

EntreMed Files New Drug Global Clinical Trial Application For ENMD-2076 With China CFDA

EntreMed (Nasdaq: ENMD) announced today that it has moved to expand its Phase 2 clinical trial for its drug candidate ENMD-2076 in advanced ovarian clear cell carcinoma (OCCC) with the submission of a new drug global clinical trial application with China's Food and Drug Administration (CFDA).  The ongoing Phase 2 trial is currently being conducted at Princess Margaret Cancer Centre in Toronto, along with participation from up to seven additional cancer centers in Canada and the U.S.

See full press release

Posted-In: News Guidance Contracts Management M&A Global

 

Related Articles (ENMD)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters